Adaptive Biotechnologies ADPT Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's noncontrolling interests in subsidiaries?
- Adaptive Biotechnologies (ADPT) reported noncontrolling interests in subsidiaries of $7.9M in Q1 2026.
- How has Adaptive Biotechnologies's noncontrolling interests in subsidiaries changed year-over-year?
- Adaptive Biotechnologies's noncontrolling interests in subsidiaries increased by 4011.4% year-over-year, from -$202K to $7.9M.
- What is the long-term trend for Adaptive Biotechnologies's noncontrolling interests in subsidiaries?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's noncontrolling interests in subsidiaries has grown at a 174.1% compound annual growth rate (CAGR), from $110K to $6.21M.
- What does noncontrolling interests in subsidiaries mean?
- This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.